[1]MOHD HANAFIAH K,GROEGER J,FLAXMAN AD,et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology,2013,57(4):1333-1342.
|
[2] WHO guide lines for the screening,care and treatment of persons with hepatitis C infection[EB/OL].[2014-04].http://www.who.int/hepatitis/publications/hepatitis-c-guidelines/en/.
|
[3]CHEN YS,LI L,CUI FQ,et al.A sero-epidemiological study on hepatitis C in China[J].Chin J Epidemiol,2011,32(9):888-891.(in Chinese)陈园生,李黎,崔富强,等.中国丙型肝炎血清流行病学研究[J].中华流行病学杂志,2011,32(9):888-891.
|
[4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol,2015,31(12):1961-1979.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.丙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1961-1979.
|
[5]CHEN XY,SHANG J,YANG RF,et al.High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients:a multicenter randomized study[J].Chin J Hepatol,2015,23(6):412-417.(in Chinese)陈新月,尚佳,杨瑞锋,等.难治性慢性丙型肝炎初治患者优化治疗后的病毒学应答率研究[J].中华肝脏病杂志,2015,23(6):412-417.
|
[6]Chinese Society of Hepatology and Chinese Society of Infectious Diseases and Parasitology,Chinese Medical Association.Guidelines for prevention and treatment of hepatitis C[J].Natl Med J China,2004,84(9):775-780.(in Chinese)中华医学会肝病学分会、传染病与寄生虫病学分会.丙型肝炎防治指南[J].中华医学杂志,2004,84(9):775-780.
|
[7] LIU CH,LIU CJ,LIN CL,et al.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection:a multicenter,randomized controlled trial[J].Clin Infect Dis,2008,47(10):1260-1269.
|
[8] ZHAO SH,CHU YL,CHENG DX,et al.Treatment with peginterferon plus ribavirin vs.interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C[J].Int J Clin Pract,2009,63(9):1334-1339.
|
[9]LINDSAY KL,MORISHIMA C,WRIGHT EC,et al.Blunted cytopenias and weight loss:new correlates of virologic null response to re-treatment of chronic hepatitis C[J].Clin Gastroenterol Hepatol,2008,6(2):234-241.
|
[10]CHUNG RT,POORDAD FF,HASSANEIN T,et al.Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C[J].Hepatology,2010,52(6):1906-1914.
|
[11]MARTINEZ-CAMACHO A,KHAOUSTOV VI,ADAM E,et al.Lymphocytosis as a predictor of poor response to treatment of hepatitis C[J].Clin Res Hepatol Gastroenterol,2011,35(1):34-40.
|
[12] CLAASSEN MA,de KNEGT RJ,JANSSEN HL,et al.Retention of CD4+CD25+FoxP 3+regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans[J].J Virol,2011,85(11):5323-5330.
|
[13] SALAZAR-MATHER TP,ORANGE JS,BIRON CA.Early murine cytomegalovirus(MCMV)infection induces liver natural killer(NK)cell inflammation and protection through macrophage inflammatory protein 1α(MIP-1α)-dependent pathways[J].J Exp Med,1998,187(1):1-14.
|
[14]CHEN XY,ZHANG YH,MA LN,et al.Changes in NK cells and regulatory T cells among patients with refractory chronic hepatitis Cduring antiviral treatment[J].J Clin Hepatol,2014,30(6):508-513.(in Chinese)陈晓云,张永宏,马丽娜,等.难治性慢性丙型肝炎患者抗病毒治疗中NK细胞和Treg细胞的动态变化[J].临床肝胆病杂志,2014,30(6):508-513.
|